Biomarin Pharmaceutical BMRN will be releasing its next round of earnings this Tuesday, August 04. For all of the relevant information, here is your guide for Tuesday's Q2 earnings announcement.
Earnings and Revenue
Biomarin Pharmaceutical EPS is expected to be around $-0.11, according to sell-side analysts. Sales will likely be near $418.61 million. Biomarin Pharmaceutical reported a per-share loss of $-0.290 when it published results during the same quarter last year. Sales in that period totaled $387.76 million. If the company were to match the consensus estimate when it reports Tuesday, EPS would have fallen 62.07%. Revenue would be up 10.7% on a year-over-year basis. Biomarin Pharmaceutical's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q1 2020 | Q4 2020 | Q3 2019 | Q2 2019 |
|---|---|---|---|---|
| EPS Estimate | 0.05 | -0.09 | 0.07 | -0.10 |
| EPS Actual | 0.44 | 0.08 | 0.30 | -0.29 |
| Revenue Estimate | 468.77 M | 459.33 M | 454.22 M | 414.40 M |
| Revenue Actual | 502.07 M | 454.44 M | 461.10 M | 387.76 M |
Stock Performance
Over the last 52-week period, shares are up 57.97%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.
Don't be surprised to see the stock move on comments made during its conference call. Biomarin Pharmaceutical is scheduled to hold the call at 16:30:00 ET and can be accessed here: https://engage.vevent.com/index.jsp?eid=6959&seid=87#/main/simplify
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
